Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.

Lilly Begins Phase III Study on Olumiant for Coronavirus

Shares of Eli Lilly & Co. LLY, -1.40% gained 7.4% in premarket trading on Tuesday after the drugmaker said its breast-cancer drug Verzenio decreased recurrence and death in certain breast-cancer patients when prescribed in combination with standard adjuvant endocrine therapy.

Lilly's shares jump on promising data from study for breast-cancer drug

INDIANAPOLIS, June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary endpoint of invasive disease-free survival (IDFS), significantly decreasing the risk of...

Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

INDIANAPOLIS, June 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's (NYSE: LLY) new rapid-acting insulin indicated to improve glycemic control in adults with...

FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin

Eli Lilly said Monday it's beginning a Phase 3 study of its rheumatoid arthritis drug, Olumiant, in coronavirus treatment. Lilly will test whether Olumiant can improve mortality rates.

Covid Report: Eli Lilly Says Its Arthritis Drug Could Tackle Coronavirus

The company is now running three separate clinical studies of treatment candidates for the novel coronavirus.

Eli Lilly Begins a Phase 3 Clinical Trial for a Potential COVID-19 Treatment

Eli Lilly is known for its Big Pharma dominance, but it's also leading cutting-edge coronavirus research. That makes LLY stock a buy here.

Eli Lilly Is a Big Pharma Play With Big Potential

Shares of Eli Lilly & Co. LLY, -0.37% were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage trial assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-19.

Lilly's shares drop as it enrolls first patient in COVID-19 study for arthritis drug

INDIANAPOLIS, June 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed...

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities of color....

Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice

INDIANAPOLIS, June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Data from this...

Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life

INDIANAPOLIS, June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting. The data being...

Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes?

This is Why Eli Lilly (LLY) is a Great Dividend Stock

Goldman Sachs

Eli Lilly's (LLY) Management at Goldman Sachs Virtual Global Healthcare Conference - Call Transcript

Eli Lilly's (LLY) Management Presents at Goldman Sachs Virtual Global Healthcare Conference (Transcript)

AbbVie

Bristol-Myers

Fortinet

NVIDIA

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.

Lilly Begins Cardiovascular Outcomes Study on Tirzepatide

It's a 144-year-old big pharma...but it's quickly become the leader in a key area of fighting COVID-19.

Here's the Surprising Coronavirus Stock You'll Really Want to Watch Right Now

Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.

Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I

INDIANAPOLIS, June 9, 2020 /PRNewswire/ -- The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist. The study will assess both...

First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial

In the latest trading session, Eli Lilly (LLY) closed at $149.21, marking no change from the previous day.

Eli Lilly (LLY) Flat As Market Gains: What You Should Know

The pharmaceutical powerhouse is developing JS016 in partnership with China-based Junshi Biosciences.

Eli Lilly Kicks Off a Clinical Trial for a Second COVID-19 Antibody Treatment

INDIANAPOLIS, June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19. The investigational...

Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment

Abbott Labs

Novavax

And they should do so even if their COVID-19 programs aren't as successful as hoped.

$3,000 Invested in These Coronavirus Stocks Could Pay Off Big Time

INDIANAPOLIS, June 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data for Olumiant® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020. Highlights from Olumiant data being presented at the virtual meeting...

News for Eli Lilly Stock (LLY)